Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma

Masayuki Miyazaki, Masayoshi Yada, Kosuke Tanaka, Takeshi Senjyu, Takeshi Goya, Kenta Motomura, Motoyuki Kohjima, Masaki Kato, Akihide Masumoto, Kazuhiro Kotoh

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Aim: To investigate the factors influenced the efficacy of tolvaptan (TLV) in liver cirrhosis. Methods: We retrospectively enrolled 61 consecutive patients with refractory hepatic ascites. All of them had been treated with furosemide and spironolactone before admission, and treated with TLV for 7 d in our hospital. The effect of TLV was defined by the rate of body weight loss, and the factors that influenced TLV efficacy were analyzed using multiple regression. Results: Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV. In stratified analysis, high doses of furosemide decreased the efficacy of TLV in patients with HCC, and increased efficacy in those without HCC. In the latter, a high Child-Pugh-Turcotte score had a positive influence and a high concentration of lactate dehydrogenase had a negative influence on the effectiveness of TLV. Conclusion: Development of ascites may differ between patients with liver failure and those with HCC progression. A sufficient preceding dose of furosemide decreases diuretic effect of TLV.

元の言語英語
ページ(範囲)5379-5385
ページ数7
ジャーナルWorld Journal of Gastroenterology
23
発行部数29
DOI
出版物ステータス出版済み - 8 7 2017

Fingerprint

Hepatocellular Carcinoma
Furosemide
Ascites
Spironolactone
tolvaptan
Liver Failure
L-Lactate Dehydrogenase
Diuretics
Liver Cirrhosis
Weight Loss
Body Weight
Liver

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Miyazaki, M., Yada, M., Tanaka, K., Senjyu, T., Goya, T., Motomura, K., ... Kotoh, K. (2017). Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology, 23(29), 5379-5385. https://doi.org/10.3748/wjg.v23.i29.5379

Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. / Miyazaki, Masayuki; Yada, Masayoshi; Tanaka, Kosuke; Senjyu, Takeshi; Goya, Takeshi; Motomura, Kenta; Kohjima, Motoyuki; Kato, Masaki; Masumoto, Akihide; Kotoh, Kazuhiro.

:: World Journal of Gastroenterology, 巻 23, 番号 29, 07.08.2017, p. 5379-5385.

研究成果: ジャーナルへの寄稿記事

Miyazaki, M, Yada, M, Tanaka, K, Senjyu, T, Goya, T, Motomura, K, Kohjima, M, Kato, M, Masumoto, A & Kotoh, K 2017, 'Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma', World Journal of Gastroenterology, 巻. 23, 番号 29, pp. 5379-5385. https://doi.org/10.3748/wjg.v23.i29.5379
Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K その他. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World Journal of Gastroenterology. 2017 8 7;23(29):5379-5385. https://doi.org/10.3748/wjg.v23.i29.5379
Miyazaki, Masayuki ; Yada, Masayoshi ; Tanaka, Kosuke ; Senjyu, Takeshi ; Goya, Takeshi ; Motomura, Kenta ; Kohjima, Motoyuki ; Kato, Masaki ; Masumoto, Akihide ; Kotoh, Kazuhiro. / Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. :: World Journal of Gastroenterology. 2017 ; 巻 23, 番号 29. pp. 5379-5385.
@article{7f5936f40d4a411680cefb6abe93f8c3,
title = "Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma",
abstract = "Aim: To investigate the factors influenced the efficacy of tolvaptan (TLV) in liver cirrhosis. Methods: We retrospectively enrolled 61 consecutive patients with refractory hepatic ascites. All of them had been treated with furosemide and spironolactone before admission, and treated with TLV for 7 d in our hospital. The effect of TLV was defined by the rate of body weight loss, and the factors that influenced TLV efficacy were analyzed using multiple regression. Results: Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV. In stratified analysis, high doses of furosemide decreased the efficacy of TLV in patients with HCC, and increased efficacy in those without HCC. In the latter, a high Child-Pugh-Turcotte score had a positive influence and a high concentration of lactate dehydrogenase had a negative influence on the effectiveness of TLV. Conclusion: Development of ascites may differ between patients with liver failure and those with HCC progression. A sufficient preceding dose of furosemide decreases diuretic effect of TLV.",
author = "Masayuki Miyazaki and Masayoshi Yada and Kosuke Tanaka and Takeshi Senjyu and Takeshi Goya and Kenta Motomura and Motoyuki Kohjima and Masaki Kato and Akihide Masumoto and Kazuhiro Kotoh",
year = "2017",
month = "8",
day = "7",
doi = "10.3748/wjg.v23.i29.5379",
language = "English",
volume = "23",
pages = "5379--5385",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "29",

}

TY - JOUR

T1 - Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma

AU - Miyazaki, Masayuki

AU - Yada, Masayoshi

AU - Tanaka, Kosuke

AU - Senjyu, Takeshi

AU - Goya, Takeshi

AU - Motomura, Kenta

AU - Kohjima, Motoyuki

AU - Kato, Masaki

AU - Masumoto, Akihide

AU - Kotoh, Kazuhiro

PY - 2017/8/7

Y1 - 2017/8/7

N2 - Aim: To investigate the factors influenced the efficacy of tolvaptan (TLV) in liver cirrhosis. Methods: We retrospectively enrolled 61 consecutive patients with refractory hepatic ascites. All of them had been treated with furosemide and spironolactone before admission, and treated with TLV for 7 d in our hospital. The effect of TLV was defined by the rate of body weight loss, and the factors that influenced TLV efficacy were analyzed using multiple regression. Results: Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV. In stratified analysis, high doses of furosemide decreased the efficacy of TLV in patients with HCC, and increased efficacy in those without HCC. In the latter, a high Child-Pugh-Turcotte score had a positive influence and a high concentration of lactate dehydrogenase had a negative influence on the effectiveness of TLV. Conclusion: Development of ascites may differ between patients with liver failure and those with HCC progression. A sufficient preceding dose of furosemide decreases diuretic effect of TLV.

AB - Aim: To investigate the factors influenced the efficacy of tolvaptan (TLV) in liver cirrhosis. Methods: We retrospectively enrolled 61 consecutive patients with refractory hepatic ascites. All of them had been treated with furosemide and spironolactone before admission, and treated with TLV for 7 d in our hospital. The effect of TLV was defined by the rate of body weight loss, and the factors that influenced TLV efficacy were analyzed using multiple regression. Results: Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV. In stratified analysis, high doses of furosemide decreased the efficacy of TLV in patients with HCC, and increased efficacy in those without HCC. In the latter, a high Child-Pugh-Turcotte score had a positive influence and a high concentration of lactate dehydrogenase had a negative influence on the effectiveness of TLV. Conclusion: Development of ascites may differ between patients with liver failure and those with HCC progression. A sufficient preceding dose of furosemide decreases diuretic effect of TLV.

UR - http://www.scopus.com/inward/record.url?scp=85026874057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026874057&partnerID=8YFLogxK

U2 - 10.3748/wjg.v23.i29.5379

DO - 10.3748/wjg.v23.i29.5379

M3 - Article

VL - 23

SP - 5379

EP - 5385

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 29

ER -